cetylpyridinium chloride anhydrous has been researched along with bortezomib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhagat, G; Furman, RR; Gardner, JR; Gonen, M; Gueorguiev, VD; Heaney, ML; Manova, K; O'Connor, OA; Paoluzzi, L; Scotto, L | 1 |
| Aicher, B; Blau, IW; Busse, A; Dabrowski, R; Lohneis, P; Reufi, B; Schmidt-Hieber, M; Thiel, E; Tietze-Buerger, C | 1 |
2 other study(ies) available for cetylpyridinium chloride anhydrous and bortezomib
| Article | Year |
|---|---|
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Health; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Membrane Potential, Mitochondrial; Mice; Microscopy, Confocal; Molecular Mimicry; Nitrophenols; Piperazines; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; Tissue Donors; Xenograft Model Antitumor Assays | 2008 |
In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors.
Topics: Annexin A5; Antigens, CD34; Boronic Acids; Bortezomib; Caspases; Colony-Forming Units Assay; Doxorubicin; Flow Cytometry; Health; Hematopoietic Stem Cells; Humans; Immunohistochemistry; Lenalidomide; Phosphorylcholine; Pyrazines; Staining and Labeling; Thalidomide; Tissue Donors; Trypan Blue | 2012 |